Head-to-head evidence
baricitinib vs tofacitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: JAK · full Rheumatoid Arthritis pipeline
baricitinib · Olumiant
Marketed by Eli Lilly
NCT01710358 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo-controlled trial using a validated composite measure of rheumatoid arthritis response, and significantly more patients responded on baricitinib than on placebo.
Next expected readout: March 2027 · NCT04870203 (registry estimate)
tofacitinib · Xeljanz
Marketed by Pfizer
NCT01262118 · Phase 1 · completed
This was a single-arm, open-label, unblinded study that tracked lipid biomarker levels before and after treatment in one group of patients, with no randomized or treated comparator arm and no statistical test of a treatment effect.
Next expected readout: January 2027 · NCT06945666 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: baricitinib's landscape · tofacitinib's landscape